SLRX Share Price | Salarius Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Salarius Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Salarius Pharmaceuticals, Inc. has a market capitalization of 2.23 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Salarius Pharmaceuticals reported net sales of 0.00 million and a net profit of -5.56 million.Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 1.51 million, while total assets were reported at 3.02 million.

Q: What does Salarius Pharmaceuticals, Inc. do?

Overview: Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company developing targeted therapies for pediatric and other cancers, including solid tumors, and operates within the Miscellaneous industry with a micro-cap market capitalization.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market-cap: USD 2.23 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.69 Return on Equity: -557.00% Price to Book: 2.23 Contact Details: Address: 2450 Holcombe Blvd Ste J-608, HOUSTON TX: 77021-2041 Tel: 1 617 8741821 Fax: 1 302 6555049 Website: http://www.flex-pharma.com/

Q: Is Salarius Pharmaceuticals, Inc. overvalued or undervalued?

As of 5 August 2022, the valuation grade for Salarius Pharmaceuticals, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is assessed as overvalued given its current financial metrics, particularly with a Price to Book Value of 1.54 and an EV to EBIT of just 0.03. Notably, the Return on Capital Employed (ROCE) is extraordinarily high at 349.78%, but this is overshadowed by a staggering Return on Equity (ROE) of -557.00%, reflecting severe losses.In comparison to its peers, Salarius Pharmaceuticals shows a stark contrast with companies like OpGen, Inc. and BTC Digital Ltd., which have P/E ratios of -2.4932 and -9.9632, respectively, indicating that they are also struggling. The lack of profitability is evident across the board, as reflected in the negative EV to EBITDA ratios for its peers. The company's stock has performed poorly over the past year, down 58.33%, while the S&P 500 has gained 10.26%, further reinforcing the notion that Salarius is overvalued in its current state.

Q: Is Salarius Pharmaceuticals, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for Salarius Pharmaceuticals, Inc. has changed from mildly bearish to mildly bullish. However, the overall stance remains mixed. The weekly MACD and RSI are bearish, while the monthly MACD is mildly bullish, indicating some potential for upward movement. The moving averages are bearish on a daily basis, and the Dow Theory shows no trend weekly but is bearish monthly. Despite this, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames, suggesting accumulation.In terms of performance, the stock has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -83.48% compared to the S&P 500's 12.22%. This stark contrast highlights the challenges facing the stock despite the recent trend change.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

81.15 k

Shareholding (Sep 2025)

FII

0.01%

Held by 3 FIIs

DII

99.85%

Held by 0 DIIs

Promoter

0.00%

How big is Salarius Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Salarius Pharmaceuticals, Inc. has a market capitalization of 2.23 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -5.56 million over the latest four quarters. As of Dec'24, shareholder's funds were 1.51 million and total assets were 3.02 million.

View full answer

What does Salarius Pharmaceuticals, Inc. do?

22-Jun-2025

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing targeted therapies for pediatric and other cancers. It has a market capitalization of $2.23 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Who are in the management team of Salarius Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Salarius Pharmaceuticals, Inc. includes Dr. William McVicar (Chairman), Mr. David Arthur (CEO), Dr. Bruce McCreedy (Interim Chief Scientific Officer), Dr. Paul Lammers (Lead Independent Director), and several independent directors: Ms. Tess Burleson, Mr. Arnold Hanish, and Mr. Jonathan Lieber. They oversee the company's strategic direction and operations.

View full answer

Is Salarius Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of August 5, 2022, Salarius Pharmaceuticals, Inc. is considered overvalued with a significant downgrade in investment appeal due to its negative Return on Equity and poor stock performance, contrasting sharply with struggling peers.

View full answer

Is Salarius Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Salarius Pharmaceuticals shows a shift from mildly bearish to mildly bullish, with mixed indicators: bearish weekly MACD and RSI, mildly bullish monthly MACD, bearish daily moving averages, and bullish On-Balance Volume, while significantly underperforming the S&P 500 with a year-to-date return of -83.48%.

View full answer

Compare Salarius Pharmaceuticals, Inc. with Similar Stocks

OpGen, Inc.Netcapital, Inc.Ontrak, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 5 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.13

Return on Equity

-117.81%

Price to Book

1.07

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-72.34%

6 Months

-90.13%

1 Year

-97.41%

2 Years

-98.84%

3 Years

-66.53%

4 Years

-99.95%

5 Years

-99.98%

Salarius Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

7.61%

EBIT to Interest (avg)

-11.50

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.69

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.10%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.54

EV to EBIT

0.03

EV to EBITDA

0.03

EV to Capital Employed

0.09

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

349.78%

ROE (Latest)

-557.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (0.14%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 41.18% vs -13.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-1.70",
          "chgp": "41.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-1.70",
          "chgp": "41.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 55.20% vs 60.44% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-12.90",
          "chgp": "55.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.60",
          "val2": "-12.50",
          "chgp": "55.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.00

-1.70

41.18%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.00

-1.70

41.18%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 41.18% vs -13.33% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.70

-12.90

55.81%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-5.60

-12.50

55.20%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 55.20% vs 60.44% in Dec 2023

All Annual Results

Company CV

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc.

Miscellaneous

Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.

Company Coordinates

Company Details

2450 Holcombe Blvd Ste J-608 , HOUSTON TX : 77021-2041

Tel: 1 617 8741821

http://www.flex-pharma.com/

Registrar Details

Salarius Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Salarius Pharmaceuticals, Inc.?

Watch in Real-Time

What does Salarius Pharmaceuticals, Inc. do?

Who are in the management team of Salarius Pharmaceuticals, Inc.?

Is Salarius Pharmaceuticals, Inc. overvalued or undervalued?

Is Salarius Pharmaceuticals, Inc. technically bullish or bearish?

Compare Salarius Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Salarius Pharmaceuticals, Inc.

Company Coordinates